<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04271735</url>
  </required_header>
  <id_info>
    <org_study_id>200044</org_study_id>
    <secondary_id>20-H-0044</secondary_id>
    <nct_id>NCT04271735</nct_id>
  </id_info>
  <brief_title>Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis</brief_title>
  <official_title>Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Psoriasis causes chronic inflammation in the body. Researchers want to see if a kind of&#xD;
      vitamin B3 dietary supplement can help. This might lead to more treatment options.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      To test if the dietary supplement nicotinamide riboside can improve immune system function in&#xD;
      the blood and skin of people with mild to moderate psoriasis.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      People ages 18-80 with mild to moderate active psoriasis not currently treated with&#xD;
      biological therapy&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participations will be screened with:&#xD;
&#xD;
        -  Medical and medication history&#xD;
&#xD;
        -  Physical exam&#xD;
&#xD;
        -  Measure of body mass index&#xD;
&#xD;
        -  Skin exam&#xD;
&#xD;
        -  Blood and urine tests&#xD;
&#xD;
      Participants will have visit 1. They will have repeats of the screening tests. They will also&#xD;
      have 2 skin biopsies. These will be from both lesions and unaffected areas. The areas will be&#xD;
      injected with a numbing medicine. A round cutting device will remove small pieces of skin&#xD;
      from each area.&#xD;
&#xD;
      Participants will take the study supplement or a placebo starting at the first visit. Neither&#xD;
      participants nor the study team will know which they receive. Participants will take capsules&#xD;
      twice daily for a total of 4 weeks.&#xD;
&#xD;
      Participants will then have visit 2. This will include the tests performed at visit 1.&#xD;
&#xD;
      Participants may by contacted by phone or email between visits to see how they are doing.&#xD;
&#xD;
      If participants develop any side effects in the 7 days after they stop taking the capsules,&#xD;
      they may have another visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Description:&#xD;
&#xD;
      Psoriasis is a Th17 linked inflammatory disease and we find that the vitamin B3 analogue&#xD;
      nicotinamide riboside (NR) blunts Th1 and Th17 activation in ex-vivo na(SqrRoot) ve and&#xD;
      differentiated T cells from control and psoriasis subjects. These findings supported the&#xD;
      proposal of the following hypothesis. Supplementation with NR will blunt systemic immune&#xD;
      activation in mild/moderate psoriasis.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        1. Evaluate the effect of NR on Th17 biology&#xD;
&#xD;
        2. Explore the effect of NR on neutrophils, specifically lowdensity granulocytes&#xD;
&#xD;
        3. Evaluate whether NR modulates keratinocyte activation in skin lesions in psoriatic&#xD;
           subjects&#xD;
&#xD;
        4. Evaluate the effect of NR on HDL regulated reverse cholesterol transport and lipid&#xD;
           composition&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      The primary outcome will be the change in the TH17 cell cytokine IL-17 secretion in response&#xD;
      to T-cell differentiation comparing the baseline versus NR or placebo. The comparisons will&#xD;
      be performed using paired two-tailed Student t-tests. Significance will be tested at&#xD;
&#xD;
      the 0.05 alpha level in this pilot study.&#xD;
&#xD;
      Secondary outcomes are:&#xD;
&#xD;
        1. Evaluate the effect of NR on the T cell transcriptome&#xD;
&#xD;
        2. Explore the effect of NR on low-density granulocytes and neutrophils&#xD;
&#xD;
        3. Evaluate whether NR modulates keratinocyte activation in skin lesions in psoriatic&#xD;
           subjects&#xD;
&#xD;
        4. Evaluate the effect of NR on HDL regulated reverse cholesterol transport and lipid&#xD;
           composition by NMR spectroscopy&#xD;
&#xD;
      Study Population:&#xD;
&#xD;
      Up to 40 male and female subjects of all races between the ages of 18-80 years with&#xD;
      mild-moderate psoriasis who live locally will be screened.&#xD;
&#xD;
      Phase:&#xD;
&#xD;
      N/A&#xD;
&#xD;
      Description of Sites/Facilities:&#xD;
&#xD;
      Enrollment and study visits will take place at the NIH Clinical Center or via telehealth&#xD;
      visits.&#xD;
&#xD;
      Enrolling Participants:&#xD;
&#xD;
      Psoriatic Subjects&#xD;
&#xD;
      Description of Study Intervention:&#xD;
&#xD;
      Nicotinamide Riboside Chloride 500mg or placebo twice daily by mouth for 28 days.&#xD;
&#xD;
      Study Duration:&#xD;
&#xD;
      3 years&#xD;
&#xD;
      Participant Duration:&#xD;
&#xD;
      5-23 weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect of NR on Th17 biology</measure>
    <time_frame>28 days</time_frame>
    <description>The primary outcome will be the change in the TH17 cell cytokine IL-17 secretion in response to T-cell differentiation comparing the baseline versus NR or placebo.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Psoriasis</condition>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <condition>Obesity</condition>
  <condition>Dyslipidemia</condition>
  <condition>Cardiometabolic Diseases</condition>
  <arm_group>
    <arm_group_label>NR arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take two capsules of nicotinamide riboside by mouth (250mg NR) twice daily for a total of 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take two capsules of nicotinamide riboside by mouth (placebo) twice daily for a total of 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Niagen</intervention_name>
    <description>Subjects will take two capsules of nicotinamide riboside by mouth (250mg NR or placebo) twice daily for a total of 4 weeks.</description>
    <arm_group_label>NR arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsule to match the active supplement</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Individuals must meet all inclusion criteria listed below in order to be eligible to&#xD;
        participate in the study.&#xD;
&#xD;
          -  Males and females between the ages of 18 and 80 with mild to moderate active&#xD;
             psoriasis.&#xD;
&#xD;
          -  Female subjects of child-bearing ability willing to commit to reliable contraception&#xD;
             while participating in the study.&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
          -  Willingness and ability to participate in required study procedures&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Severe psoriasis by PASI (Psoriasis Area and Severity Index) score &gt; 12&#xD;
&#xD;
          -  Currently being treated with biologic immune modifying agents.&#xD;
&#xD;
          -  Currently on treatment for allergies or other inflammatory diseases.&#xD;
&#xD;
          -  Currently taking a multivitamin, Vitamin B or tryptophan supplementation and unwilling&#xD;
             to stop within 2 weeks of baseline visit.&#xD;
&#xD;
          -  Unwillingness/inability to provide informed consent&#xD;
&#xD;
          -  ALT &gt; x3 upper limit of normal, hepatic insufficiency or active liver disease&#xD;
&#xD;
          -  Recent history of acute gout&#xD;
&#xD;
          -  Chronic renal insufficiency with creatinine &gt; 2.5mg/dl&#xD;
&#xD;
          -  Pregnant (or attempting to become pregnant) women&#xD;
&#xD;
          -  Current participation in another drug study&#xD;
&#xD;
          -  History of intolerance to NR precursor compounds, including niacin or nicotinamide&#xD;
&#xD;
          -  Study adherence concerns&#xD;
&#xD;
          -  Individuals with diabetes type 1 and 2 who use insulin&#xD;
&#xD;
          -  Women of child-bearing potential unwilling to use contraception or unwilling to&#xD;
             practice abstinence&#xD;
&#xD;
          -  Breastfeeding women unwilling to stop breastfeeding&#xD;
&#xD;
          -  Immunization administered within 30 days of participation and no plans for&#xD;
             immunization while participating in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael N Sack, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca D Huffstutler, C.R.N.P.</last_name>
    <phone>(301) 594-1281</phone>
    <email>rebecca.huffstutler@nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2020-H-0044.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>November 9, 2021</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Inflammatory Skin Disease</keyword>
  <keyword>Systemic Inflammation-Induced Atherosclerosis</keyword>
  <keyword>TH17 Cell Cytokine IL-17 Secretion in Response to T-cell Differentiation</keyword>
  <keyword>Effect of NR on Neutrophils</keyword>
  <keyword>Effect of NR on HDL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

